Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
AFP elevation
i
Other names:
AFP, Alpha-fetoprotein, FETA, HPAFP
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
174
Related biomarkers:
Expression
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
sorafenib + LY2157299
Sensitive: C2 – Inclusion Criteria
sorafenib + LY2157299
Sensitive
:
C2
sorafenib + LY2157299
Sensitive: C2 – Inclusion Criteria
sorafenib + LY2157299
Sensitive
:
C2
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
AFP elevation
Rectal Cancer
AFP elevation
Rectal Cancer
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
bevacizumab + atezolizumab
Resistant: C3 – Early Trials
bevacizumab + atezolizumab
Resistant
:
C3
bevacizumab + atezolizumab
Resistant: C3 – Early Trials
bevacizumab + atezolizumab
Resistant
:
C3
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
AFP elevation
Prostate Cancer
AFP elevation
Prostate Cancer
etoposide IV + bleomycin
Sensitive: C4 – Case Studies
etoposide IV + bleomycin
Sensitive
:
C4
etoposide IV + bleomycin
Sensitive: C4 – Case Studies
etoposide IV + bleomycin
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login